Chris J. Van Koppen

Saarbruecken, SL 66123, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Potent Dual Inhibitors of Steroid Sulfatase and 17β-Hydroxysteroid Dehydrogenase Type 1 with a Suitable Pharmacokinetic Profile for In Vivo Proof-of-Principle Studies in an Endometriosis Mouse Model.

Potent Dual Inhibitors of Steroid Sulfatase and 17β-Hydroxysteroid Dehydrogenase Type 1 with a Suitable Pharmacokinetic Profile for In Vivo Proof-of-Principle Studies in an Endometriosis Mouse Model.

Journal: Journal of medicinal chemistry

Published: June 27, 2023

17β-Hydroxysteroid Dehydrogenase Type 1 Inhibition: A Potential Treatment Option for Non-Small Cell Lung Cancer.

17β-Hydroxysteroid Dehydrogenase Type 1 Inhibition: A Potential Treatment Option for Non-Small Cell Lung Cancer.

Journal: ACS medicinal chemistry letters

Published: August 27, 2021

Fluorescent small-molecule agonists as follicle-stimulating hormone receptor imaging tools.

Fluorescent small-molecule agonists as follicle-stimulating hormone receptor imaging tools.

Journal: RSC chemical biology

Published: May 14, 2020

Molecular mechanisms of posaconazole- and itraconazole-induced pseudohyperaldosteronism and assessment of other systemically used azole antifungals.

Molecular mechanisms of posaconazole- and itraconazole-induced pseudohyperaldosteronism and assessment of other systemically used azole antifungals.

Journal: The Journal of steroid biochemistry and molecular biology

Published: November 19, 2019

Profiling of anabolic androgenic steroids and selective androgen receptor modulators for interference with adrenal steroidogenesis.

Profiling of anabolic androgenic steroids and selective androgen receptor modulators for interference with adrenal steroidogenesis.

Journal: Biochemical pharmacology

Published: October 30, 2019

Design, Synthesis, and Biological Characterization of Orally Active 17β-Hydroxysteroid Dehydrogenase Type 2 Inhibitors Targeting the Prevention of Osteoporosis.

Design, Synthesis, and Biological Characterization of Orally Active 17β-Hydroxysteroid Dehydrogenase Type 2 Inhibitors Targeting the Prevention of Osteoporosis.

Journal: Journal of medicinal chemistry

Published: July 26, 2019

Development of potential preclinical candidates with promising in vitro ADME profile for the inhibition of type 1 and type 2 17β-Hydroxysteroid dehydrogenases: Design, synthesis, and biological evaluation.

Development of potential preclinical candidates with promising in vitro ADME profile for the inhibition of type 1 and type 2 17β-Hydroxysteroid dehydrogenases: Design, synthesis, and biological evaluation.

Journal: European journal of medicinal chemistry

Published: April 17, 2019

Effects of 17β-HSD2 inhibition in bones on osteoporosis based on an animal rat model.

Effects of 17β-HSD2 inhibition in bones on osteoporosis based on an animal rat model.

Journal: The Journal of steroid biochemistry and molecular biology

Published: March 04, 2019

Targeted Endocrine Therapy: Design, Synthesis, and Proof-of-Principle of 17β-Hydroxysteroid Dehydrogenase Type 2 Inhibitors in Bone Fracture Healing.

Targeted Endocrine Therapy: Design, Synthesis, and Proof-of-Principle of 17β-Hydroxysteroid Dehydrogenase Type 2 Inhibitors in Bone Fracture Healing.

Journal: Journal of medicinal chemistry

Published: January 16, 2019

Highly Potent 17β-HSD2 Inhibitors with a Promising Pharmacokinetic Profile for Targeted Osteoporosis Therapy.

Highly Potent 17β-HSD2 Inhibitors with a Promising Pharmacokinetic Profile for Targeted Osteoporosis Therapy.

Journal: Journal of medicinal chemistry

Published: November 28, 2018

Accelerated skin wound healing by selective 11β-Hydroxylase (CYP11B1) inhibitors.

Accelerated skin wound healing by selective 11β-Hydroxylase (CYP11B1) inhibitors.

Journal: European journal of medicinal chemistry

Published: September 13, 2017

Lead Optimization Generates CYP11B1 Inhibitors of Pyridylmethyl Isoxazole Type with Improved Pharmacological Profile for the Treatment of Cushing's Disease.

Lead Optimization Generates CYP11B1 Inhibitors of Pyridylmethyl Isoxazole Type with Improved Pharmacological Profile for the Treatment of Cushing's Disease.

Journal: Journal of medicinal chemistry

Published: June 02, 2017

Showing 1-12 of 22

Last Updated: 09/26/2026